An old drug with a new purpose

The drug in question is rapamycin, a medication doctors typically prescribe to prevent organ transplant rejection and to treat certain rare diseases. Before joining the University of Missouri, Lin had already studied rapamycin's effects on the brain in animals. Her earlier work showed that the drug can slow brain aging and improve brain blood flow in mice carrying APOE4.

For the new study, Lin wanted to find out whether those benefits extend to humans. She recruited adults aged 45 to 65 who carry the APOE4 variant but had not yet developed any symptoms of Alzheimer's disease — in other words, people who are healthy today but face an elevated risk in the future.

Participants, both with and without the gene variant, took a low dose of rapamycin every day for four weeks. When Lin measured blood flow in their brains, a clear pattern emerged: only those carrying APOE4 showed improvement. Participants without the variant showed no comparable change.

That selectivity matters. It suggests the drug may specifically help preserve cognitive function in people at higher risk of Alzheimer's, rather than acting as a general brain booster for everyone.

A stronger effect in women

The study also revealed a sex difference. "We also found that females with APOE4 saw the greatest improvement in brain blood flow, which is significant given that nearly two-thirds of people with Alzheimer's are women," Lin said. "This research is an example of precision medicine, as we work to identify who can benefit from this drug the most."

Precision medicine, in this context, means tailoring prevention to the people most likely to respond — here, APOE4 carriers, and particularly women.

Important caveats

The results are encouraging but preliminary. The paper, authored by Chetan Aware and colleagues, describes a pilot single-arm trial, meaning all participants received the drug and there was no placebo control group for comparison. The treatment period was short — just four weeks — and the study measured blood flow, not memory or thinking skills directly. So while improved blood flow is a promising sign, the research does not yet show that rapamycin prevents Alzheimer's disease or cognitive decline in APOE4 carriers.

Longer, larger controlled trials would be needed to confirm the findings and to test whether the improvements in blood flow translate into preserved cognition over time. Whether rapamycin, a drug with known effects on the immune system, can be used safely for long-term prevention in healthy adults also remains an open question.

Still, the study adds to a growing body of evidence that targeting the biological processes of brain aging — rather than waiting for symptoms — could one day change how doctors approach Alzheimer's disease, especially for the millions of people born with the APOE4 variant.